VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 78 filers reported holding VAXCYTE INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,576 | +15.8% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q1 2024 | $1,361 | +11.0% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q4 2023 | $1,226 | +23.7% | 20,000 | 0.0% | 0.00% | +50.0% |
| Q3 2023 | $991 | +2.8% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $964 | +33.5% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $722 | -23.4% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $943 | -99.7% | 20,000 | +48.1% | 0.00% | +100.0% |
| Q3 2022 | $328,000 | +18.4% | 13,500 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $277,000 | -14.8% | 13,500 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $325,000 | +9.8% | 13,500 | +9.8% | 0.00% | 0.0% |
| Q4 2021 | $296,000 | -5.7% | 12,300 | +2.5% | 0.00% | 0.0% |
| Q3 2021 | $314,000 | +16.7% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $269,000 | +20.6% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $223,000 | -33.2% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $334,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $59,882,148 | 46.04% |
| Darwin Global Management, Ltd. | 2,080,946 | $163,916,116 | 19.07% |
| RA Capital Management | 8,203,754 | $619,465,465 | 8.19% |
| ACUTA CAPITAL PARTNERS, LLC | 110,400 | $8,336,304 | 7.02% |
| COMMODORE CAPITAL LP | 1,305,000 | $98,540,550 | 6.73% |
| Saturn V Capital Management LP | 215,680 | $16,285,997 | 6.15% |
| Cormorant Asset Management, LP | 1,100,000 | $83,061,000 | 4.80% |
| Kynam Capital Management, LP | 753,240 | $56,877,152 | 4.39% |
| Novo Holdings A/S | 950,000 | $71,734,500 | 4.16% |
| Frazier Life Sciences Management, L.P. | 1,039,405 | $78,485,472 | 3.67% |